Sürdürülebilir Kalkınma Amaçları
Yayınlar
- MakaleYalnız künye2021The effect of homocysteine on the expression of CD36, PPARγ, and C/EBPα in adipose tissue of normal and obese mice
Mentese, Ahmet; Dogramaci, Seniz; Demir, Selim; Yaman, Serap Ozer; Ince, Imran; Altay, Diler Us; Erdem, Mehmet; Turan, Ibrahim; Alver, Ahmet
The purpose of this study was to investigate the effect of homocysteine (Hcy) on CD36, PPARγ, and C/EBPα gene and protein expression in adipose tissue obtained from normal and high-calorie diet obesity models. CD36, PPARγ, and C/EBPα gene expression and protein levels in adipose tissue specimens were determined using the RT-PCR and ELISA methods, respectively. Significantly increased CD36 gene expression was observed in adipose tissue from obese mice, while Hcy significantly reduced CD36 gene expression in adipose tissue from normal and obese mice. PPARγ and C/EBPα gene expression levels decreased significantly in all groups compared to the normal group. In addition, levels of both PPARγ and C/EBPα gene expression were lower with Hcy supplementation compared to their own controls. In conclusion, Hcy’s reduction of CD36 gene expression in adipose tissue may be one probable factor in hyperhomocysteinemia representing an independent risk factor for cardiovascular diseases.
- MakaleAçık Erişim2020The Value of Cardiotrophin-1 in the Diagnosis, Severity, and Prognosis of Pulmonary Embolism
Pasli, Sinan; Asik, Olgun; Imamoglu, Melih; Çiçek, Mustafa; Yadigaroglu, Metin; Dogramaci, Seniz; Mentese, Ahmet; Sahin, Mursel; Tatli, Ozgur
Aim: Pulmonary embolism (PE) is a life-threatening condition that requires early diagnosis and treatment. There is still a need for precise and non-invasive biomarkers that can be used to diagnose PE. This study aimed to determine the diagnostic value of Cardiotrophin-1 (CT-1) in patients with acute PE and ascertain the relationship between serum CT-1 level and disease prognosis and severity. Materials and Methods: In this prospective study, the serum CT-1 levels of 165 patients with suspected acute PE were measured. The patients were divided into two groups, PE (+) and PE (-), based on their computed tomography angiography results. Their serum CT-1 levels were compared. Results: The CT-1 levels of the PE (+) group (median=4.18 pg/mL, range=3.57-9.55 pg/mL) was non-significantly (p=0.08) different from those of the PE (-) group (median=4.38 pg/mL, range=3.57-51.64 pg/mL). Based on the severity of the condition, there were significant differences (p=0.001) in the CT-1 levels of the patients in the intermediate-low risk group (median=4.19 pg/mL, range=3.62-5.32 pg/mL), intermediate-high risk group (median=4.06 pg/mL, range=3.57-9.31 pg/mL) and high risk group (median=5.01 pg/mL, range=3.89-9.55 pg/mL). Based on the clinical course, the CT-1 levels of the patients in the good clinical course group (median=4.15 pg/mL, range=3.57-9.31 pg/ml) were significantly different (p=0.004) from those in the poor clinical course group (median=4.53 pg/mL, range=3.66-9.55 pg/mL). Conclusion: CT-1 level was not observed to be a precise biomarker for the diagnosis of acute PE. However, our study demonstrated that the serum CT-1 levels can be used as a biomarker for ascertaining the severity and prognosis of patients with PE.